ArdorComm Media Group

Saturday, March 14, 2026 11:37 AM

oncology

Kidney Cancer Cases Could Nearly Double Worldwide by 2050: Study

ardorcomm news

A new global study warns that kidney cancer cases may almost double over the next quarter century if current health trends continue. Researchers from Europe, the US, and the UK examined data from the Global Cancer Observatory of the International Agency for Research on Cancer, projecting a dramatic surge in both incidence and mortality. In 2022, around 435,000 new cases and 156,000 deaths from kidney cancer were recorded worldwide. By 2050, the figures could rise to nearly 746,000 cases (a 72% increase) and over 304,000 deaths (a 96% rise), according to findings published in European Urology. The rise is linked largely to modifiable risk factors such as obesity, hypertension, diabetes, smoking, and physical inactivity, alongside environmental exposures. While 5–8% of cases are estimated to have a genetic basis, researchers emphasized that more than half of all kidney cancer cases are preventable. “Kidney cancer is becoming a global health challenge. Clinicians and policymakers must brace for this sharp increase,” said senior author Alexander Kutikov, Chair of the Department of Urology at Fox Chase Cancer Center in the US. He noted that lifestyle interventions—including maintaining a healthy weight, controlling blood sugar and blood pressure, and quitting smoking—can substantially reduce risk. The study also revealed wide geographical and gender-based disparities in incidence and survival. Five-year survival rates currently range between 40% and 75%, with wealthier nations expected to benefit from early detection through routine imaging and better access to advanced treatments such as surgery and radiotherapy. The findings add to a broader global concern: a recent Lancet analysis estimated that annual cancer deaths of all types may climb by 75% over the next 25 years. Alarmingly, 40% of these deaths are linked to 44 preventable risk factors, including poor diet, tobacco, and high blood sugar. Source: PTI

Kidney Cancer Cases Could Nearly Double Worldwide by 2050: Study Read More »

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. (Citius Pharma) has announced that shareholders of TenX Keane Acquisition (TenX) have approved the merger with Citius Pharma’s oncology subsidiary. The new public company will be named Citius Oncology, Inc. The merger, approved by the boards of both companies, is expected to close soon, pending certain conditions. This merger aims to enhance Citius Oncology’s access to public equity markets, support the commercialization of LYMPHIR, if approved, and explore additional oncology opportunities. Leonard Mazur, Chairman and CEO of Citius Pharma, expressed optimism about the merger’s potential to unlock value in their oncology assets. The agreement involves TenX acquiring Citius Pharma’s oncology subsidiary, converting shares into common stock of Citius Oncology. Upon closing, Citius Pharma will hold about 65.6 million shares of Citius Oncology, representing roughly 90% ownership. Additionally, Citius Pharma will contribute $10 million in cash, with TenX’s remaining trust account cash aiding Citius Oncology’s working capital. The transaction is detailed in the merger agreement, filed in a Current Report on Form 8-K with the SEC. Advisors for the transaction include Maxim Group LLC for Citius Pharma, Newbridge Securities Corporation for TenX, and legal advisors Wyrick Robbins Yates & Ponton LLP for Citius Pharma and The Crone Law Group P.C. for TenX. Citius Oncology will focus on developing and commercializing novel oncology therapies, with LYMPHIR aiming for FDA approval to treat cutaneous T-cell lymphoma (CTCL). The market for LYMPHIR is estimated to exceed $400 million, with robust intellectual property protections supporting its competitive positioning. If approved, LYMPHIR could be available by Q4 2024.

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. Read More »